You just read:

Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy

News provided by

Audentes Therapeutics, Inc.

Sep 21, 2017, 08:00 ET